EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study

Daisuke Aoki iD, Tsutomu Tabata iD, Satoshi Yanagida iD, Toshiaki Nakamura iD, Eiji Kondo iD, Junzo Hamanishi iD, Kenichi Harano iD, Kosei Hasegawa iD, Takeshi Hirasawa iD, Kensuke Hori iD, Shinichi Komiyama iD, Motoki Matsuura iD und 13 weitere

Journal of Gynecologic Oncology · 2024

DOI: 10.3802/jgo.2024.35.e114 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Daisuke Aoki und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Indazoles, Ovarian Neoplasms, Piperidines, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: TPC, Takeda Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the long-term efficacy and safety of niraparib in Japanese women with heavily pretreated ovarian cancer. METHODS: This was the follow-up analysis of a phase 2, multicenter, open-label, single-arm study in Japanese women with homologous recombination-deficient, platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who had completed 3-4 lines of chemotherapy and were poly(ADP-ribose) polymerase inhibitor naïve. Participants received niraparib (starting dose, 300 mg) once daily in continuous 28-day cycles until objective disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was confirmed objective response rate (ORR), as assessed using Response Evaluation Criteria in Solid Tumors version 1.1. Safety evaluations included treatment-emergent adverse events (TEAEs). RESULTS: 20 patients were enrolled in the study and included in both efficacy and safety analyses. Median total study duration was 759.5 days. Median dose intensity was 201.3 mg/day. Confirmed ORR was 60.0% (90% confidence interval [CI]=39.4-78.3); 2 patients had complete response and 10 patients had partial response. Median duration of response was 9.9 months (95% CI=3.9-26.9) and the disease control rate was 90.0% (95% CI=68.3-98.8). The most common TEAEs were anemia (n=15), nausea (n=12), and decreased platelet count (n=11). TEAEs leading to study drug dose reduction, interruption, or discontinuation were reported in 16 (80.0%), 15 (75.0%), and 2 patients (10.0%), respectively. CONCLUSION: The long-term efficacy and safety profile of niraparib was consistent with previous findings in the equivalent population in non-Japanese patients. No new safety signals were identified. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03759600.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndazolesOvarian NeoplasmsPiperidinesPoly(ADP-ribose) Polymerase InhibitorsAdultAgedFemaleHumansMiddle AgedCarcinoma, Ovarian EpithelialEast Asian PeopleFallopian Tube NeoplasmsHomologous RecombinationJapanPeritoneal NeoplasmsPhthalazines

Stichwörter der Autor:innen

Clinical Trial, Phase IIOvarian CancerPoly(ADP-ribose) Polymerase Inhibitors

Substanzen

IndazolesniraparibPhthalazinesPiperidinesPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
  • Akasaka Sanno Medical Center, International University of Health and Welfare Graduate School, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, Tokyo Women's Medical University, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima, Japan.
  • Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Mie, Japan.

ORCID-Profile: Daisuke Aoki, Tsutomu Tabata, Satoshi Yanagida, Toshiaki Nakamura, Eiji Kondo, Junzo Hamanishi, Kenichi Harano, Kosei Hasegawa, Takeshi Hirasawa, Kensuke Hori, Shinichi Komiyama, Motoki Matsuura, Hidekatsu Nakai, Hiroko Nakamura, Jun Sakata, Kazuhiro Takehara, Munetaka Takekuma, Yoshihito Yokoyama, Yoichi Kase, Shuuji Sumino, Junpei Soeda, Ai Kato, Ajit Suri, Aikou Okamoto, Toru Sugiyama

Förderung

  • TPC
  • Takeda Pharmaceutical Company

Zitieren

APA

Aoki, D., Tabata, T., Yanagida, S., Nakamura, T., Kondo, E., Hamanishi, J., Harano, K., Hasegawa, K., Hirasawa, T., Hori, K., Komiyama, S., Matsuura, M., Nakai, H., Nakamura, H., Sakata, J., Takehara, K., Takekuma, M., Yokoyama, Y., Kase, Y., …, & Sugiyama, T. (2024). Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e114

Vancouver

Aoki D, Tabata T, Yanagida S, Nakamura T, Kondo E, Hamanishi J, et al. Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e114

BibTeX
@article{Aoki2024,
  author = {Aoki, Daisuke and Tabata, Tsutomu and Yanagida, Satoshi and Nakamura, Toshiaki and Kondo, Eiji and Hamanishi, Junzo and Harano, Kenichi and Hasegawa, Kosei and Hirasawa, Takeshi and Hori, Kensuke and Komiyama, Shinichi and Matsuura, Motoki and Nakai, Hidekatsu and Nakamura, Hiroko and Sakata, Jun and Takehara, Kazuhiro and Takekuma, Munetaka and Yokoyama, Yoshihito and Kase, Yoichi and Sumino, Shuuji and Soeda, Junpei and Kato, Ai and Suri, Ajit and Okamoto, Aikou and Sugiyama, Toru},
  title = {Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  doi = {10.3802/jgo.2024.35.e114}
}
Kostenlos starten →